Ryan, DK; Karhunen, V; Walker, DJ; Gill, D
(2021)
Inhibition of interleukin 6 signalling and renal function: a Mendelian randomization study.
Br J Clin Pharmacol, 87 (7).
pp. 3000-3013.
ISSN 1365-2125
https://doi.org/10.1111/bcp.14725
SGUL Authors: Gill, Dipender Preet Singh Walker, Drew James
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
|
|
PDF
Accepted Version
Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Inhibition of interleukin 6 (IL-6) signalling has been proposed as a potential cardioprotective strategy for patients with chronic kidney disease (CKD), but the direct effects of IL-6 inhibition on renal function are not known. A Mendelian randomization (MR) study was performed to investigate the association of genetically proxied inhibition of IL-6 signalling with estimated glomerular filtration rate (eGFR), CKD and blood urea nitrogen (BUN). Inverse-variance weighted MR was used as the main analysis, with sensitivity analyses performed using simple median, weighted median and MR-Egger methods. There was no evidence for an association of genetically proxied inhibition of IL-6 signalling (scaled per standard deviation unit decrease in C-reactive protein) with log eGFR (0.001, 95% confidence interval -0.004 - 0.007), BUN (0.009, 95% confidence interval -0.003 - 0.021) and CKD (odds ratio 0.948, 95% confidence interval 0.822 - 1.094). These findings do not raise concerns for IL-6 signalling having large adverse effects on renal function.
Item Type: | Article | ||||||||
---|---|---|---|---|---|---|---|---|---|
Additional Information: | © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | ||||||||
Keywords: | Interleukin-6, Mendelian randomisation study, cardiovascular disease, chronic kidney disease, Interleukin-6, Mendelian randomisation study, cardiovascular disease, chronic kidney disease, 1115 Pharmacology and Pharmaceutical Sciences, Pharmacology & Pharmacy | ||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) Academic Structure > Institute of Medical & Biomedical Education (IMBE) |
||||||||
Journal or Publication Title: | Br J Clin Pharmacol | ||||||||
ISSN: | 1365-2125 | ||||||||
Language: | eng | ||||||||
Dates: |
|
||||||||
Publisher License: | Publisher's own licence | ||||||||
Projects: |
|
||||||||
PubMed ID: | 33393675 | ||||||||
Go to PubMed abstract | |||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/112773 | ||||||||
Publisher's version: | https://doi.org/10.1111/bcp.14725 |
Statistics
Actions (login required)
![]() |
Edit Item |